These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 9380353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG.
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG, Maltezos A, Mantziris DA, Sine CS, Stewart WC.
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [Abstract] [Full Text] [Related]

  • 5. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
    Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M.
    Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M.
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
    Yüksel N, Altintaş O, Karabaş L, Alp B, Cağlar Y.
    Ophthalmologica; 1999 May; 213(4):228-33. PubMed ID: 10420106
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
    Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, van Buskirk EM.
    Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
    [Abstract] [Full Text] [Related]

  • 12. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
    Nagasubramanian S, Hitchings RA, Demailly P, Chuniaud M, Pannarale MR, Pecori-Giraldi J, Stodtmeister R, Parsons DG.
    Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmic Surg Lasers; 1996 Sep; 27(9):806-9. PubMed ID: 8878205
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
    Simsek S, Ertürk H, Demirok A, Cinal A, Yasar T, Karadenizli C.
    Eur J Ophthalmol; 1998 Sep; 8(3):167-72. PubMed ID: 9793771
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.